Drug Information

General Information
Drug ID
DR01277
Drug Name
Entecavir
Synonyms
2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one-water (1/1); 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; 9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate; BMS-200475; Baraclude; Baraclude (TN); ETV; Entecavir (INN); Entecavir (USAN); Entecavir hydrate; Entecavir hydrate (JAN); Entecavir monohydrate; SQ-34676
Drug Type
Small molecular drug
Indication Chronic hepatitis B infection [ICD11: 1E51.0] Approved [1]
Therapeutic Class
Antiviral Agents
Structure
3D MOL 2D MOL
Formula
C12H15N5O3
Canonical SMILES
C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N
InChI
InChI=1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1
InChIKey
QDGZDCVAUDNJFG-FXQIFTODSA-N
CAS Number
CAS 142217-69-4
Pharmaceutical Properties Molecular Weight 277.28 Topological Polar Surface Area 126
Heavy Atom Count 20 Rotatable Bond Count 2
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 5
XLogP
-1.3
PubChem CID
135398508
PubChem SID
17398002 , 37101953 , 49830936 , 56391942 , 57379683 , 91749140 , 99319526 , 104253461 , 118313779 , 124757591 , 125001900 , 125164395 , 126651626 , 134222146 , 136920321 , 137129051 , 137179356 , 152034465 , 162011500 , 162183301 , 163370951 , 163908003 , 164825059 , 164833113 , 172087090 , 172440023 , 174531851 , 175265673 , 180672743 , 186013131 , 196106268 , 198991663 , 210274904 , 210280539 , 223379249 , 223398838 , 226415922 , 249739265 , 251893489 , 252110220 , 252162333 , 252316076
ChEBI ID
CHEBI:473990
TTD Drug ID
D0KR2J
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
CNT2 Transporter Info Concentrative nucleoside transporter 2 Substrate [2]
CNT3 Transporter Info Concentrative Na(+)-nucleoside cotransporter 3 Substrate [2]
ENT1 Transporter Info Equilibrative nucleoside transporter 1 Substrate [2]
ENT2 Transporter Info Equilibrative nucleoside transporter 2 Substrate [2]
OAT2 Transporter Info Organic anion transporter 2 Substrate [3]
OCT-3 Transporter Info Organic cation transporter 3 Substrate [2]
OCTN2 Transporter Info Organic cation/carnitine transporter 2 Substrate [2]
PEPT2 Transporter Info Peptide transporter 2 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data CNT2 Transporter Info Km = 53.2 microM Madin-Darby canine kidney (MDCK) cells-hCNT2 [2]
CNT3 Transporter Info Km = 23.1 microM Madin-Darby canine kidney (MDCK) cells-hCNT3 [2]
References
1 Entecavir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
3 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
4 The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.